Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics Inc. (symbol: CYTK) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of pioneering muscle activators. With a primary goal of addressing debilitating diseases where muscle performance is compromised, Cytokinetics is at the forefront of muscle biology research.
Specializing in muscle function and contractility, Cytokinetics has developed small molecule drug candidates aimed at enhancing muscle performance. The company’s innovative treatments target diseases such as amyotrophic lateral sclerosis (ALS), heart failure, spinal muscular atrophy (SMA), and chronic obstructive pulmonary diseases (COPD).
Some of the key investigational medicines in the pipeline include:
- CK-4021586 (CK-586): A cardiac myosin inhibitor showing promise in the treatment of cardiac diseases.
- Aficamten: Designed to improve heart muscle function in chronic heart failure patients.
- Omecamtiv Mecarbil: Another advanced therapy aimed at boosting heart muscle performance.
With a strong emphasis on improving the quality of life for patients with severe cardiovascular and neuromuscular diseases, Cytokinetics is committed to groundbreaking research and development. The company's strategic partnerships and collaborations support its mission to bring effective treatments to market, providing hope to patients worldwide.
Recently, Cytokinetics has been actively engaged in investor events and webcasts, sharing forward-looking statements and updates about its latest achievements and ongoing projects. The company's commitment to transparency and investor relations has established it as a reliable entity in the biopharmaceutical industry.
For more detailed updates and news, visit here, here, here, and here.
For investor inquiries, please contact Diane Weiser, Senior Vice President of Corporate Affairs, at (415) 290-7757.
Cytokinetics (CYTK) has initiated AMBER-HFpEF, a Phase 2 clinical trial for CK-586 in patients with symptomatic heart failure with preserved ejection fraction (HFpEF). The study is designed as a randomized, placebo-controlled, double-blind, multi-center, dose-finding trial, specifically targeting patients with LVEF ≥60%.
CK-586, a cardiac myosin inhibitor, is being developed to treat a subgroup of HFpEF patients with hypercontractility and ventricular hypertrophy. The trial's focus on HFpEF patients is significant as approximately half of heart failure patients have this condition, characterized by ejection fraction ≥50%, impaired diastolic function, and elevated NTpro-BNP.
The development strategy builds on similarities between a subset of HFpEF patients and those with non-obstructive hypertrophic cardiomyopathy (nHCM), leveraging data from aficamten in nHCM.
Cytokinetics (CYTK) has announced its 2025 milestones and Vision 2030 strategic plan. The company anticipates a PDUFA target action date of September 26, 2025 for aficamten, its cardiac myosin inhibitor for obstructive HCM. Key 2025 milestones include preparing for aficamten's U.S. commercial launch in 2H 2025, expanding European commercial readiness for potential EMA approval in 1H 2026, and supporting potential approval in China in 2H 2025.
The company will report topline results from MAPLE-HCM Phase 3 trial in 1H 2025, complete enrollment for ACACIA-HCM Phase 3 trial and CEDAR-HCM pediatric trial in 2H 2025. Additionally, Cytokinetics continues patient enrollment in COMET-HF for omecamtiv mecarbil and plans to complete enrollment of initial cohorts in AMBER-HFpEF for CK-586.
Vision 2030 objectives include advancing two approved products across three indications, developing ten novel molecular entities, reaching over 100,000 patients globally, and expanding access to medicines in more than 15 countries throughout North America and Europe.
Cytokinetics (CYTK) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Robert I. Blum, will deliver a presentation on Monday, January 13, 2025, at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco.
Interested investors and stakeholders can access the presentation through a live webcast available on the Investors & Media section of the Cytokinetics website. The recording will remain accessible on the company's website for 90 days following the event's conclusion.
Cytokinetics (CYTK) has announced inducement grants to 9 new employees who joined in December 2024. The grants include:
- 52,188 stock options at $47.04 per share (closing price on Dec 31, 2024), vesting over 4 years with 1/4th after first year and 1/48th monthly thereafter
- 33,885 restricted stock units (RSUs) vesting over 3 years (40% after year 1, 40% after year 2, 20% after year 3)
- 3,189 performance stock units (PSUs) tied to two performance goals, with 50% of earned shares vesting upon goal certification and 50% one year later
All grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment, subject to continued service requirements.
Cytokinetics (CYTK) announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for aficamten, a cardiac myosin inhibitor designed to treat obstructive hypertrophic cardiomyopathy (HCM). The application will be reviewed by the Committee for Medicinal Products for Human Use (CHMP).
The MAA is supported by results from the SEQUOIA-HCM Phase 3 clinical trial, published in the New England Journal of Medicine. This follows the FDA's acceptance of aficamten's New Drug Application (NDA) in the US, which has a PDUFA target action date of September 26, 2025. The drug is also under regulatory review in China.
Cytokinetics (CYTK) has granted equity-based compensation to 7 new employees who joined in November 2024. The package includes 34,515 stock options at an exercise price of $51.86 per share and 22,410 restricted stock units (RSUs).
The RSUs will vest over 3 years: 40% after year one, 40% after year two, and 20% after year three. The stock options will vest over 4 years: 25% after the first year, with the remaining vesting monthly over 36 months. The options have a 10-year term. These grants were made as employment inducements under Nasdaq Rule 5635(c)(4).
Cytokinetics (CYTK) announced the start of COMET-HF, a confirmatory Phase 3 clinical trial evaluating omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction. The trial, conducted with Duke Clinical Research Institute, will enroll approximately 1,800 patients randomized 1:1 to receive omecamtiv mecarbil or placebo. The primary endpoint is time to first event in a composite of cardiovascular death, first heart failure event, LVAD implantation, cardiac transplantation, or stroke. Eligible patients must have ejection fraction <30%, NT-proBNP ≥1,000 pg/mL, and a heart failure event within six months. The study includes a two-week run-in period and two-week washout period before randomization.
Cytokinetics (CYTK) has announced its participation in two major investor conferences this December. The company will join the 7th Annual Evercore ISI HealthconX Conference for a fireside chat on December 3, 2024, at 9:35 AM ET in Coral Gables, FL. Additionally, they will participate in the 36th Annual Piper Sandler Healthcare Conference on December 4, 2024, at 8:00 AM ET in New York.
Both fireside chats will be accessible via live webcast through Cytokinetics' website's Investors & Media section, with recordings available for 90 days after the events.
Cytokinetics (CYTK) announced FDA acceptance of its New Drug Application (NDA) for aficamten, a cardiac myosin inhibitor for treating obstructive hypertrophic cardiomyopathy (HCM). The FDA set a PDUFA target date of September 26, 2025, with standard review and no planned advisory committee meeting.
The NDA is supported by SEQUOIA-HCM Phase 3 trial results, which showed significant improvement in exercise capacity with aficamten versus placebo. The drug demonstrated positive impacts on exercise capacity, clinical outcomes, and cardiac biomarkers, with statistically significant improvements in all 10 prespecified secondary endpoints. Treatment-emergent serious adverse events were lower in the aficamten group (5.6%) compared to placebo (9.3%).
Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and joint development plans, with Bayer conducting Phase 3 trials for obstructive HCM in Japan while Cytokinetics expands its ACACIA-HCM and CEDAR-HCM trials into the region.
FAQ
What is the current stock price of Cytokinetics (CYTK)?
What is the market cap of Cytokinetics (CYTK)?
What does Cytokinetics Inc. specialize in?
What are some key drug candidates being developed by Cytokinetics?
Which diseases are targeted by Cytokinetics' treatments?
What recent achievements has Cytokinetics announced?
How does Cytokinetics contribute to muscle biology research?
Who can be contacted for investor relations at Cytokinetics?
Where can I find more detailed updates and news about Cytokinetics?
What is the focus of Cytokinetics’ investigational medicines?
What makes Cytokinetics' approach unique?
What platforms does Cytokinetics use for investor communication?
